[{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chimerix","amount2":0.37,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.37,"dosageForm":"Tablet","sponsorNew":"Chimerix \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Chimerix \/ BARDA"},{"orgOrder":0,"company":"Chimerix","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chimerix","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Chimerix \/ Emergent BioSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Chimerix \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Chimerix","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chimerix","amount2":0.33000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.33000000000000002,"dosageForm":"Tablet","sponsorNew":"Chimerix \/ Emergent BioSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Chimerix \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Chimerix","sponsor":"Public Health Agency of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chimerix","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Chimerix \/ Public Health Agency of Canada","highestDevelopmentStatusID":"15","companyTruncated":"Chimerix \/ Public Health Agency of Canada"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Food and Drug Administration","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimerix \/ Food and Drug Administration","highestDevelopmentStatusID":"8","companyTruncated":"Chimerix \/ Food and Drug Administration"},{"orgOrder":0,"company":"Chimerix","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ONC206","moa":"Dopamine D2 receptor (D2R)","graph1":"Oncology","graph2":"Phase I","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimerix \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Chimerix \/ National Institutes of Health"},{"orgOrder":0,"company":"Chimerix","sponsor":"Chimerix","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"Dopamine D2 receptor (D2R)||DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimerix \/ Chimerix","highestDevelopmentStatusID":"8","companyTruncated":"Chimerix \/ Chimerix"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"Dopamine D2 receptor (D2R)||DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Oncoceutics Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Chimerix","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Chimerix","highestDevelopmentStatusID":"8","companyTruncated":"Chimerix \/ Chimerix"},{"orgOrder":0,"company":"Chimerix","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0.93999999999999995,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.93999999999999995,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0.93999999999999995,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.93999999999999995,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Chimerix","sponsor":"Oncoceutics Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Chimerix","highestDevelopmentStatusID":"8","companyTruncated":"Chimerix \/ Chimerix"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dociparstat","moa":"Heparanase","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dociparstat Sodium","moa":"heparin derivatives","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dociparstat Sodium","moa":"heparin derivatives","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Chimerix \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Chimerix

Chimerix
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check all FDF Dossiers for
this supplier

Contact Us
PharmaScopic.com

Chimerix

VISIT THE VIRTUAL BOOTH, Contact Details

DIGITAL CONTENT

Interview #SpeakPharma, Vlog #PharmaReel, Data Compilation #PharmaFlow, 93 News #PharmaBuzz

DEVELOPMENTS

46 Drugs in Development

46 Drugs in Development

FINISHED DOSAGE FORMULATIONS

1 FDF Dossiers, 1 FDA Orange Book

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Chimerix

U.S.A

The MedTech Conference

Not Confirmed

02

Chimerix

U.S.A

The MedTech Conference

Not Confirmed

03

Chimerix

U.S.A

The MedTech Conference

Not Confirmed

04

Chimerix

U.S.A

The MedTech Conference

Not Confirmed

05

Chimerix

U.S.A

The MedTech Conference

Not Confirmed

06

Chimerix

U.S.A

The MedTech Conference

Not Confirmed

07

Chimerix

U.S.A

The MedTech Conference

Not Confirmed

08

Chimerix

U.S.A

The MedTech Conference

Not Confirmed

09

Chimerix

U.S.A

The MedTech Conference

Not Confirmed

10

Chimerix

U.S.A

The MedTech Conference

Not Confirmed